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Received July 29, 2014; accepted October 24, 2015AbstractBackground: The results of studies measuring the number of endothelial progenitor cells (EPCs) in normal pregnancies and in preeclampsia have
been highly controversial or even contradictory because of cross-sectional designs and different methodologies enumerating three distinct
subsets of EPCs: circulating angiogenic cells (CAC), colony-forming unit endothelial cell (CFU-ECs), and endothelial colony forming cells
(ECFCs). To provide a clear explanation for these underlying controversies, we designed a prospective study to compare the number of all EPC
subsets between three trimesters of normal gestation and a caseecontrol study to compare these values as preeclampsia occurs with those from
gestational age (GA) matched normal pregnancy.
Methods: Samples from peripheral blood of nine women were taken during their three consecutive trimesters of normal pregnancy, and from
eight women with preeclampsia. To cover most of the reported phenotypes for CACs and ECFCs in the literature, we enumerated 13 cell
populations by quantitative flow cytometry using various combinations of the markers CD34, CD133, CD309, and CD45. We used routine
culturing techniques to enumerate CFU-ECs.
Results: The numbers of CACs and ECFCs were higher in women with preeclampsia ( p ¼ 0.014). By contrast, preeclampsia was associated with
a reduced number of CFU-ECs ( p ¼ 0.039). The CAC number rose with the increase in GA ( p ¼ 0.016) during normal pregnancy, while the
number of CFU-ECs and ECFCs did not differ during the trimesters.
Conclusion: Although we did demonstrate an increase in absolute counts of CACs and ECFCs in preeclampsia, fewer colony formation ca-
pacities indicated a loss in their functional capabilities. By contrast, the number of CACs increased without alterations in colony formation
ability in normal pregnancy with the growth of the fetus. Here, by comparing different methodologies to calculate the number of EPC subsets,
we could imitate the existing controversy in the literature for such calculations, which may help to elucidate clearer explanations.
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Normal pregnancy is associated with enhanced endothelial
function and formation of new blood vessels. Regulation of
endothelial function requires an interaction between endo-
thelial cells and subpopulations of circulating cells, termed
endothelial progenitor cells (EPCs).1 Since first explained by
Asahara et al,2 the definition of EPCs and techniques used for
their assessment have gone through many changes. Hill and
coworkers3 introduced a colony-forming assay [colony
forming unit (CFU)-Hill] in the field, and Peichev et al4
suggested the combination of CD34, CD133, and CD309 as
the flow cytometric identifying the phenotype for EPCs.
However, more recent data are also persuasive, further sug-
gesting that the two mentioned methods introduce cells that
exhibit monocyte characteristics (such as expressing CD14
and CD45) in conjunction with markers from endothelial
lineage (such as CD34 and CD309), which are from a he-
matopoietic hierarchy. These cells do not differentiate into
endothelial cells or assemble into vascular networks in vitro,
and thus cannot be true EPCs.5 Eventually, Ingram et al6
discovered cells with more appropriate characteristics as
true EPCs, the so-called endothelial colony-forming cells
(ECFCs). Based on that, ECFCs express CD34 and CD309
but lack CD14, CD45, and CD133.6 Despite these, both CFU-
Hills and circulating EPCs measured by flow cytometry
remained under the classification umbrella of EPCs in the
literature but they were renamed as CFU-endothelial cells
(CFU-ECs) and circulating angiogenic cells (CACs),
respectively.5,7 Nevertheless, reduced CFU-EC and CAC
numbers correlate with increased risk of vascular disease and
the strong correlation between their numbers and abnormal
function of endothelial cells cannot be ignored.5
In this regard, only a few studies have been performed
regarding the role of EPCs in normal pregnancies and pre-
eclampsia, as an example of gestational vascular disorder, and
the results of those studies are highly controversial.8 This may
be due to the variety of surface markers, and functional assays
have been used to assess EPC numbers that make the com-
parison between their results more difficult. Furthermore, all
of these studies were cross-sectional and relatively few studies
used both flow cytometry and culture techniques to compare
EPC subsets. Therefore, using flow cytometry and culturing
techniques in a prospective study, we compared the number of
all EPC subsets including: CACs, CAC precursors
(CD34CD133þCD309þ cells),9 putative ECFCs, and CFU-
ECs in three trimesters of normal pregnancy and in a case-
econtrol study the similar values from patients with pre-
eclampsia were compared with the findings from gestational
age-matched normal pregnancies.
2. Methods2.1. Study populationNine healthy women in their first trimester of pregnancy
were enrolled in this study. The participants were followed-upduring their total course of pregnancy from April 2011 to
May 2012 and peripheral blood samples were taken sequen-
tially in each trimester. The exclusion criteria consisted of
affliction with diabetes mellitus, malignancies, autoimmune
disease, hypertension, chest pain induced by physical activ-
ities, vascular claudication, current episode of infection, and a
family history of premature cardiac events or severe abnormal
lipid profiles. Eight pregnant women diagnosed with pre-
eclampsia, defined as the new onset of hypertension (systolic
blood pressure  140 mmHg and diastolic blood
pressure  90 mmHg) and proteinurea ( 0.3 g in a 24-hour
urine specimen) after 20 weeks of gestation in a previously
normotensive woman were recruited in the study.7 All par-
ticipants gave their written informed consent before enrol-
ment in this study. This study was approved by the local
Ethics Committee and conformed to the Declaration of
Helsinki.2.2. Preparation of mononuclear cellsPeripheral blood samples (20 mL) were taken, diluted using
15 mL of phosphate buffered saline (PBS), and brought onto
the layer of Lymphosep (Biosera, Boussens, France). They
were then centrifuged at 300g continuously for 25 minutes and
finally the layer of mononuclear cells (MNCs) was isolated.
The total number of isolated cells was determined using he-
mocytometer and the purified cells were divided into two tubes
for the following steps.2.3. CFU-EC assayHalf of the isolated MNCs were resuspended in 4 mL of
Endocult medium (Stem Cell Technologies, Vancouver, BC,
Canada) supplemented with 100 U/mL penicillin and
100 mg/mL streptomycin (Gibco/Invitrogen, Carlsbad, CA,
USA). Two-milliliter aliquots of this suspension was seeded
per well of 6-well fibronectin-coated plates (BD Bio-
sciences, San Jose, CA, USA) and incubated for 2 days at
37C, 5% CO2, and 95% humidity. Afterwards, the non-
adherent cells were harvested by flushing prewarmed media
and replated in 96-well fibronectin-coated plates (BD Bio-
sciences). After 5 days, the culture medium was removed
and the plates washed with PBS to remove nonadherent
cells. To increase the accuracy, the tests were done in
duplicate and the colonies were counted by two independent
expert technicians.2.4. Quantitative flow cytometryBecause of the low frequency of the target cells in the
peripheral blood, our flow cytometry protocols followed rare
cell analysis protocols.10 Consequently, all the mononuclear
cells purified from half of the blood sample (equivalent to
10 mL or at least 106 cells) were stained and analyzed through
flow cytometry. Propidium iodide and dead cell removal kits
(Miltenyi Biotec, Bergisch Gladbach, Germany) were used
before the actual staining to exclude dead cells from the
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bindings.10 The isolated cells were stained with antibodies
against CD34-fluorescein isothiocyanate, CD133- phycoery-
thrin, CD309-allophycocyanin, and CD45-peridinin chloro-
phyll protein while the cells were treated with Fc receptor
blocking reagent (all obtained from Miltenyi Biotec). Cell
suspensions were incubated in the dark at 4e8C and washed
twice; the cell pellets were resuspended in 520 mL of PBS-Number of events in target region  number of beads in the tube=number of events in bead region  sample volume:EDTA buffer supplemented with 2% fetal bovine serum. To
enumerate cell population of interest, TruCOUNT kit (BD
Biosciences) was used. Accordingly, stained cell suspensions
were transferred to the TruCOUNT tubes and immediately
analyzed by four-color FACS-Calibur instrument (BD Bio-
sciences). Isotype matched antibodies (Miltenyi Biotec) wereFig. 1. Typical dot plot diagrams defining some of the variable regions used t
CD34þCD133þCD309þCD45þ cells.used to exclude nonspecific staining of the cells in every
staining. CellQuest Pro software (BD Biosciences) was used
for data acquisition and WinMDI software was used for data
analysis and graphical presentation of data. Fig. 1 shows the
way that cells were gated for analysis and enumeration of the
desired cells. The absolute cell count per mL of blood samples
was calculated by the formula provided in the TruCOUNT kit
instructions:We considered CD34þCD133þCD309þCD45þ cells as
CACs,5 CD34þCD133 CD309þCD45 as ECFCs,6 and
CD34CD133þCD309þ cells as CAC precursors.9 In addition,
to cover other reported phenotypes for CACs and ECFCs in
the literature,11 we enumerated 10 other cell populations listed
in Tables 1 and 2.5,11,17,18,20e23o enumerate absolute counts of the circulating angiogenic cells marked as
Table 1
Enumeration data for 10 putative endothelial progenitor cell populations during three gestational trimesters produced by flow cytometry analysis.
Groups Used as
alternative
for
Reference 1st trimester 2nd trimester 3rd trimester Statistical analysis ( p)
Variables Median (range) Median (range) Median (range) 1st & 2nd 1st & 3rd 2nd & 3rd
CD34þ/mL d d 13,880 (3794e472,929) 6670 (2594e23,641) 17,004 (6222e29,187) 0.063 0.605 0.024
CD309þ/mL d d 8693 (2516e52,947) 3445 (1442e7383) 7284 (5489e10,598) 0.077 0.546 0.004*
CD133þ/mL CAC 11 11,069 (3743e39,230) 6993 (2382e11,589) 11,774 (6555e20,566) 0.113 0.387 0.006*
CD34þ 133þ/mL CAC 20 4156 (1491e34,144) 4061 (1090e6045) 5606 (2976e8422) 0.436 0.190 0.031
CD34þ 309þ/mL CAC 21 359 (121e4481) 160 (58e503) 380 (59e691) 0.094 0.489 0.222
CD133þ 45/mL CAC 22 375 (30e2123) 192 (33e1490) 139 (34e449) 0.489 0.094 0.436
CD133þ 309þ/mL CAC 23 713 (465e1543) 493 (351e852) 1197 (681e2544) 0.050 0.063 < 0.001*
CD34þ 45/mL ECFC 17 1704 (12e87,502) 260 (62e4115) 124 (18e3984) 0.094 0.050 0.258
CD309þ 45/mL ECFC 18 623 (167e25,092) 614 (48e3310) 996 (277e4546) 0.605 0.387 0.258
CD34þ 133 309þ/mL ECFC 5 36 (7e255) 29 (5e157) 158 (11e292) 0.387 0.258 0.063
CD34þ/106 cells d d 5780 (1999e112,276) 3423 (1267e6285) 6996 (1153e10,258) 0.094 0.931 0.094
CD309þ/106 cells d d 2258 (566e19,327) 1536 (662e6956) 2286 (1134e3836) 0.546 0.796 0.190
CD133þ/106 cells CAC 11 3278 (1695e9313) 2812 (1094e7339) 5074 (1271e7939) 0.387 0.863 0.258
CD34þ 133þ/106 cells CAC 20 1252 (799e8106) 1216 (602e3826) 2263 (577e3663) 0.605 0.387 0.297
CD34þ 309þ/106 cells CAC 21 169 (16e3169) 63 (32e189) 84 (11e303) 0.222 0.436 0.546
CD133þ 45/106 cells CAC 22 74 (24e504) 118 (4e824) 55 (10e99) 0.863 0.077 0.258
CD133þ 309þ/106 cells CAC 23 397 (64e653) 207 (89e427) 480 (172e669) 0.489 0.436 0.040
CD34þ 45/106 cells ECFC 17 507 (6e13,720) 123 (37e999) 58 (8e751) 0.136 0.031 0.136
CD309þ 45/106 cells ECFC 18 245 (23e9159) 191 (26e3119) 412 (54e842) 0.863 0.730 0.546
CD34þ 133 309þ/106 cells ECFC 5 29 (1e104) 14 (3e59) 38 (2e134) 0.489 0.489 0.190
*p < 0.017 considered statistically significant.
1st, 2nd, 3rd ¼ trimesters; CAC ¼ circulating angiogenic cells; ECFC ¼ endothelial colony forming cells; GA ¼ gestational age.
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with flowcytometry and those for CFU-EC derived from
culturing techniques were calculated in 1 mL of whole blood
or in 106 purified MNCs to address the controversies in theTable 2
Enumeration data for 10 putative endothelial progenitor cell populations in pree
analysis.
Groups Used as alternative for Reference GA
Variable Median
CD34þ/mL d d 11,964
CD133þ/mL d d 11589
CD309þ/mL CAC 11 7383
CD34þ 133þ/mL CAC 20 5172
CD34þ 309þ/mL CAC 21 161
CD133þ 45/mL CAC 22 181
CD133þ 309þ/mL CAC 23 1014
CD34þ 45/mL ECFC 17 192
CD309þ 45/mL ECFC 18 1324
CD34þ 133 309þ/mL ECFC 5 47.5
CD34þ/106 cells d d 4823
CD133þ/106 cells d d 3455
CD309þ/106 cell CAC 11 2551
CD34þ 133þ/106 cells CAC 20 1783.5
CD34þ 309þ/106 cells CAC 21 80
CD133þ 45/106 cells CAC 22 50
CD133þ 309þ/106 cells CAC 23 345
CD34þ 45/106 cells ECFC 17 68
CD309þ 45/106 cells ECFC 18 334
CD34þ 133 309þ/106 cells ECFC 5 14
*p < 0.05 considered statistically significant.
CAC ¼ circulating angiogenic cells; ECFC ¼ endothelial colony forming cells; Gliterature. Eventually, 28 parameters were gathered for com-
parison between the three trimesters or between preeclampsia
with GA-matched normal pregnancies. The number of cells is
reported as mean ± standard deviation. Normality of the dis-
tribution of continuous data was examined using the Kolmo-
goroveSmirnov test. Logarithmic transformation wasclamptic and GA matched normal pregnancies produced by flow cytometry
-matched normal pregnancy Preeclampsia p
Min Max Median Min Max
4347 36,025 13813 4644 61155 0.622
3888 25693 11,458 5693 44,323 0.733
2871 17,920 11,233 5499 57,134 0.381
2007 21,340 3573 1302 11,501 0.205
59 691 520.5 38 1589 0.154
34 488 449.5 90 1309 0.023*
452 2544 1352.5 1072 4893 0.112
18 4116 315 55 6795 0.791
272 4546 3880 1264 13309 0.014*
6 292 139 8 748 0.267
1153 10,258 6155 1470 8621 0.267
1271 7939 4431 1802 6157 0.569
1134 6956 4181 1740 5522 0.066
577 3826 1189.5 412 2265 0.178
11 303 212 12 267 0.132
7 338 148.5 53 284 0.029*
171 669 596 339 833 0.014*
8 999 103 32 657 0.733
54 3119 1129 680 1879 0.008*
2 134 71.5 2 82 0.178
A ¼ gestational age.
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analyzed using Friedman one-way analysis of variance with
repeated measures and Bonferroni's post-tests for multiple
comparisons. Additionally, KruskaleWallis and Man-
neWhitney U tests were used where appropriate. The p value
< 0.05 when comparing two groups, or p < 0.017 when
comparing three groups, were considered as significant in
analyses. SPSS software version 19.0 for windows (IBM,
Armonk, NY, USA) was used for statistical analysis. Prism
(GraphPad Software, San Diego, CA, USA) was used for
graphical presentation of data.
3. Results3.1. Samples and participantsIn this study, we compared the number of EPC subsets in
the peripheral blood samples from nine normal pregnant
women and eight patients with preeclampsia. The mean
gestational age of the patients with preeclampsia and gesta-
tional age matched normal pregnant women were 32.29 weeks
and 31.8 weeks, respectively, which were not significantly
different ( p ¼ 0.641). Some of the clinical characteristics of
the patients with preeclampsia and of healthy pregnancies in
subsequent trimesters are shown in Table 3.3.2. Quantification of EPC subsetsFlow cytometry was used to enumerate CACs, precursors
of CAC and putative populations of ECFCs, and culture
techniques were used to enumerate the number of CFU-ECs,
both in 1 mL of blood and in 106 purified MNCs.
There were higher numbers of CFU-ECs when comparing
per mL of blood during the first trimester of the normal
pregnancies (27.8 colonies/mL) than the second and third
trimesters with slightly higher numbers in the third trimester
compared to the second (16.72 colonies/mL and 24.02 col-
onies/mL, respectively; Fig. 2A). Nevertheless, neither of the
observed variations during normal pregnancy was significantTable 3
Clinical profiles of the individuals with normal pregnancy or preeclampsia.
General characteristics of norm
Maternal age (y) 29.33 ± 4.58 (21e36)
Nuliparity (%) 55.6
1st trimester
Gestational age at the day of sampling (wk) 9.8 ± 1.7 (7e13)
Systolic blood pressure (mmHg) 108.8 ± 9.2 (100e120)
Diastolic blood pressure (mmHg) 67.7 ± 8.3 (60e80)
Urine protein (dipstick) 0þ
Gestational age matched norm
Number of samples 9
Maternal age (y) 29 ± 4.6 (21e36)
Nuliparity (%) 53
Gestational age at the day of sampling (wk) 31.8 ± 3.3 (27e36)
Systolic blood pressure (mmHg) 107.19 ± 10.64 (90e120)
Diastolic blood pressure (mmHg) 63.13 ± 8.3 (60e80)
Urine protein (dipstick) 0þ
Data are presented as mean ± SD unless otherwise indicated.( p ¼ 0.322). The number of CFU-ECs when determined in
106 MNCs showed no significant change either (Fig. 2B,
p ¼ 0.181). The frequency of CACs found in the unit of the
peripheral blood was significantly elevated as gestational age
increased in normal pregnancies. For example, CAC frequency
was 106.25 cells/mL during the first trimester, and increased to
239 cells/mL in the third trimester (Fig. 2C; p ¼ 0.016).
However, the increase showed no significance when numbers
of CACs were calculated among 106 MNCs (Fig. 2D,
p ¼ 0.136). The number of precursors of CACs in 1 mL of
blood rose as gestational age increased (Fig. 2E, p < 0.001)
and again this rise was insignificant when the numbers were
calculated among 106 MNCs (Fig. 2F, p ¼ 0.019). Measuring
the frequencies of ECFCs by the mentioned phenotypes did
not show a significant variation during different trimesters of
normal pregnancies (Fig. 2G and H, p ¼ 0.031). In addition to
those populations, the actual frequencies of 10 other cell
populations expressing various combinations of surface
markers from the peripheral blood of women with normal
pregnancy are listed in Table 1.
We found significantly higher numbers of CFU-EC per mL
of blood in the gestational age matched normal pregnant women
compared with preeclamptic patients (Fig. 3A, p ¼ 0.039).
When extrapolating the data in 106 MNCs, this significance was
lost (Fig. 3B, p¼ 0.078). The counts of CACs per 1 mL of blood
and in 106 MNCs had a difference that was not statistically
significant (Fig. 3C and D, p ¼ 0.205 and p ¼ 0.235, respec-
tively). The number of CAC precursors counted among 106
MNCs was also significantly higher in the preeclampsia group
(Fig. 3F, p¼ 0.029). The analysis of the ECFC numbers showed
no considerable difference between the two studied groups
(Fig. 3G and H, p ¼ 0.677). Absolute numbers from 10 other
cell populations expressing various combinations of surface
markers in normal and diseased states are shown in Table 2.
4. Discussion
In the present study, through flow cytometric studies we
could show that higher numbers of CACs and ECFCs subsetsal pregnancies
2nd trimester 3rd trimester
24.7 ± 2.1 (22e27) 33.6 ± 2.6 (31e38)
107.6 ± 11.2 (90e120) 106.8 ± 9.2 (90e120)
68.7 ± 7.3 (60e80) 67.9 ± 9.1 (60e80)
0þ 0þ
al pregnancies Preeclamptic pregnancies p
8 d
29.7 ± 7.1 (17e37) 0.782
14 0.036
32.29 ± 3.09 (26e35) 0.641
160 ± 14.14 (150e180) 0.012
99.29 ± 8.3 (90e115) 0.032
~2.5þ 0.021
Fig. 2. Box plot defining median and range from 10 of the calculated values in three gestational trimesters (*p < 0.017). The number of circulating angiogenic cells
(CACs) increases as gestational age advances, and reaches the significance level when reported as numbers in 1 mL of blood ( p ¼ 0.016). Number of CAC
precursors increases as gestational age increases as well. Numbers of colony forming unit endothelial cells (CFU-ECs) and endothelial colony forming cells
(ECFCs) did not vary significantly.
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preeclampsia compared with normal pregnancies, but with
lower colony-forming capacities (shown by CFU-EC assay).
By contrast, the number of these cells increases as gestation
goes ahead in a healthy pregnancy and their functional ca-
pacities remain intact in this setting. The pattern of these
changes and their significance is open to comparison of these
results with those from previous studies, as discussed below.
In this regard, some controversies have been previously
reported about the frequency of EPCs in different trimesters of
normal pregnancies as well as in preeclampsia. This might be
related to several factors. First of all, there is a lack of
consensus on the definitive EPC phenotype and a variety of
surface markers, and functional assays have been used to
enumerate these cells. Besides, the resultant data are reported
in two ways: numbers in the volume of blood and frequencies
in a defined number of MNCs, which makes the comparisonFig. 3. Box plot defining median and range from 10 calculated values in the group
(*p < 0.05). The number of colony-forming unit endothelial cells (CFU-ECs) decre
numbers in 1 mL of blood ( p ¼ 0.039). The number of circulating angiogenic ce
preeclampsia group. Numbers of CACs and endothelial colony forming cells (ECFof different clinical studies difficult. Furthermore, some
technical issues were not taken into consideration. For
example, in flow cytometric studies, Matsubara et al12 did not
perform an absolute count of the cells, while Buemi et al13 did
that only on the CD34þ population, and none of the studies
analyzed a sufficient number of cells as needed in the settings
of rare cell analysis.10 In addition, the absence of a prospec-
tive approach, at least in part, could explain some of the
existing variations among reported results. Therefore, in this
prospective study we analyzed all the EPC subsets by
considering the suggested patterns in flow cytometry and
culture techniques. Moreover, the counts were determined
both by calculating the number of cells in the unit volume of
blood and the number of cells in 106 purified MNCs. Com-
parison of these two methods of data calculation showed a
significant difference in the final results which is discussed
below in comparison with previous studies.with preeclampsia and gestational age matched the normal pregnancy group
ases as preeclampsia occurs and reaches the significance level when reported as
ll (CAC) precursors measured among 106 mononuclear cells increased in the
Cs) increased without statistical significance. NL ¼ normal.
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significant increase in CFU-ECs when calculating the cells
among 1.5  106 MNCs along the gestation time. By contrast,
Savvidou et al15 reported only minor decreases in CFU-ECs
calculated among MNCs with progression of pregnancy. Our
finding was more consistent with the results of Savvidou et al,15
reporting EPCs as CFU-ECs counted among 106 MNCs.
Similar to our findings, Matsubara et al12 showed a decrease in
CFU-ECs in the unit volume of blood as gestational age
increased. However, we could see some increase afterwards
during the third trimester. Regarding the number of CACs, our
data were in accordance with the report by Buemi et al,13 which
showed an increase in the number of CACs in 1 mL of blood
with progress in gestational ages. However, our data contra-
dicted results found by Matsubara et al,12 who concluded that
the frequency of CACs in 105 MNCs decreased with gestational
age. In our study, the number of CD34CD133þCD309þ cells
that had been purposed to be precursors of CACs9 increased
significantly as gestational age increased.
Similar to the findings of Sugawara et al16 and Lin et al,7
we could also show the presence of reduced CFU-ECs
among a defined number of MNCs in patients with pre-
eclampsia compared with the gestational age-matched normal
pregnancies. In the same way, we showed a lower frequency of
CFU-ECs in 1 mL of blood of patients with preeclampsia
although it was in contrast with the findings of Matsubara
et al.12 In our study, consistent with the report by Buemi
et al,13 the number of CACs in 1 mL of blood increased in
preeclampsia. However, the calculated numbers in 106 purified
MNCs were in disagreement with the results reported by
Matsubara et al.12 The number of precursors of CACs was also
significantly higher in the preeclampsia group.
In our study, we used a flow cytometric technique to
enumerate the possible ECFCs. We found a higher number of
all possible combination markers as preeclampsia occurred,
although only CD309þCD45 profile reached statistical sig-
nificance. This is in accordance with the findings in acute
myocardial infarction; as endothelial damage occurs, the
number of ECFCs rises in the peripheral blood.17,18 In regards
to the normal pregnancy, we did not find any significant dif-
ferences in the number of possible ECFCs with changes in
gestational age. Here, we dispensed with culturing techniques
to enumerate ECFCs because the frequency of these cells in
the peripheral blood is very low, and large volumes of blood
samples are needed for accurate measurements. So, most of
our participants refused to donate such volumes of blood in
their pregnancy period. In addition, it is shown that the number
of culture-derived ECFCs colonies strongly correlated with the
number of CD34þCD45 and CD34þCD309þ flow cytometric
enumerated cells and without any correlation to the
CD34þCD133þ as marker of CACs.17,18
Due to the biological functions of EPCs, the differences
between the number of CACs and CFU-ECs in normal preg-
nancies and those with preeclampsia can be expected. It was
shown that EPCs can be mobilized from the bone marrow
during stress or endothelial injuries (as it happens in pre-
eclampsia or acute myocardial infarction), which results in anincreased number of cells in the peripheral blood.19 In fact,
this can be an attempt to promote re-endothelialization of the
damaged vessels. However, the functionality of these cells can
be affected by chronic inflammation in vascular disorders.3
Accordingly, in our study there were increased numbers of
CACs and ECFCs in the blood of patients with preeclampsia,
possibly as a result of mobilization. However, due to inflam-
mation, the cells were incapable of performing their normal
function, which was demonstrated by lower abilities for col-
ony formation. By contrast, among the higher gestational ages
of a normal pregnancy, as the fetus grows the demand for EPC
rises and the number of CACs increases with normal func-
tional capability for colony formation.
These findings emphasize again the importance of EPCs as
a target for biological therapies of preeclampsia and other
vascular diseases. Moreover, by comparing different method-
ologies to calculate the number of EPC populations, or
considering different populations as target, we could imitate
the existing controversy in the literature for such calculations,
which may help to extract more clear explanations. Prospec-
tive studies should be conducted to determine whether or not
measuring the EPC numbers in early pregnancy can help
predict the occurrence of preeclampsia.
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